Recruiting

Multi-center Study on New Cardiovascular Remodeling and Function Parameters in Hypertension

I'm interested View official listing

ClinicalTrials.gov IDNCT05638503

PhaseNot Applicable

Enrollment2200

SponsorQilu Hospital of Shandong University

Age30 Years – 75 Years

SexALL

I'm interested View official listing

Conditions studied

Hypertension

About this study

The investigators want to explore the relationship between different configurations of hypertension and the incidence of cardiovascular events by the guidelines reference range and EMINCA recommended reference range. Then the investigators want to enroll twenty research centers and 2200 hypertensions were planned to be collected and followed up in the 12th, 24th, 36th and 48th months after being enrolled in this study. Physical examination, ECG examination, laboratory examination, echocardiography and carotid ultrasound should be taken when baseline and follow-up. Echocardiographic measurement parameters were analyzed and the relationship between the echocardiographic measurement parameters and cardiovascular events and prognosis of hypertension.

Interventions

Other: Left ventricular hypertrophy — Hypertension with normal left ventricular geometry and left ventricular concentric remodeling
Other: Left ventricular non-hypertrophy — Hypertension with left ventricular concentric hypertrophy and left ventricular eccentric hypertrophy

Primary outcomes

Emerging atrial fibrillation (Through study completion, on average once a year.)
Emerging unstable angina, myocardial infarction, heart failure, coronary revascularization, cardiovascular death (Through study completion, on average once a year.)
Emerging transient ischemic attack (TIA) or stroke (Through study completion, on average once a year.)

Eligibility information

Inclusion Criteria: 1. Age 30-75 years old; 2. No antihypertensive drugs were used and three blood pressure measurements were conducted on different days, with systolic blood pressure ≥ 140 mmHg (1 mmHg=0.133 kPa) and/or diastolic blood pressure ≥ 90 mmHg; or have a history of hypertension and are using antihypertensive drugs, even if the blood pressure is lower than 140/90 mmHg; 3. Left ventricular ejection fraction was normal (LVEF ≥ 0.5). 4. All patients agreed to participate in the experiment and signed the informed consent form. Exclusion Criteria: 1. Secondary hypertension caused by renal parenchymal diseases, renal vascular diseases, coarctation of aorta and endocrine system diseases; 2. Severe cardiovascular and cerebrovascular diseases; heart valve disease; persistent atrial fibrillation and severe arrhythmia; previously undergone cardiovascular disease surgery; 3. Abnormal liver function; abnormal renal function and diabetes; 4. Pregnant or breastfeeding women; 5. Expected survival time due to non-cardiovascular disease\<4 years; 6. Patients with poor echocardiographic image quality.

Study locations

Qilu Hospital of Shandong University, Jinan, Shandong 250012 China

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-12.